Table 2.
Time to disease progression and PFS by drug category and treatment line – from chart review
| Variable | First-line treatment | n | # Censored obs.a | Median (months) | 95% confidence interval | p-valueb | |
|---|---|---|---|---|---|---|---|
| Lower limit | Upper limit | ||||||
| Time to disease progression on first-line therapy (months) from start of first-line therapy | Aromatase inhibitors | 103 | 8 | 12.0 | 10.0 | 13.1 | |
| Chemotherapy | 25 | 13 | 7.9 | 6.0 | 8.3 | ||
| Other | 50 | 8 | 11.9 | 7.0 | 17.3 | 0.3563 | |
| Progression- free survival on second line therapy (months) from start of second-line therapy | Aromatase inhibitors | 103 | 16 | 7.4 | 5.7 | 8.4 | |
| Chemotherapy | 25 | 8 | 7.3 | 5.1 | 11.2 | ||
| Other | 50 | 19 | 8.1 | 7.0 | 12.0 | 0.1047 | |
| Progression- free survival on third-line therapy (months) from start of third-line therapy | Aromatase inhibitors | 55 | 23 | 8.0 | 3.4 | 12.0 | |
| Chemotherapy | 11 | 6 | 9.0 | 1.4 | NE | ||
| Other | 20 | 7 | 5.2 | 4.0 | 14.1 | 0.9176 | |
PFS Progression-free survival; NE Not Estimable
aCensored patients are patients who have not had an event of disease progression, either because they dropped out from the trial for reasons other than disease progression or because they had not progressed when data were cut-off. b log rank test